OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

October 18th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

October 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Dr. Hope on the Detection Sensitivity of PSMA-PET Scanning

October 17th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

Dr. Young Discusses Using Anticoagulants in Children With Cancer

October 17th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses using anticoagulants in children with cancer.

Dr. Wierda Discusses Sequencing New Agents in CLL

October 17th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia.

Dr. Awan Discusses Challenges With Ibrutinib in CLL

October 16th 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

October 16th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Choueiri on the Research With Immunotherapy in RCC

October 14th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer

October 14th 2017

Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

October 13th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer

October 13th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.

Dr. Kumar on Properly Managing Patients With Multiple Myeloma

October 13th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

Dr. Pal on the CheckMate-214 and CABOSUN Studies in RCC

October 13th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

October 13th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies

October 13th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.

Dr. Ross on Biomarker Research Development in Liver Metastasis

October 11th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Dr. Eskelund on Outcomes of TP53-Mutated MCL

October 11th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

October 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.

Dr. Wierda Discusses the Role of Ibrutinib in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.

Dr. Callander Discusses Combinations in Multiple Myeloma

October 11th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.